Static List Review November 2015
NICE Technology Appraisal Guidance No.118; Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (recommendation 1.1)
Static List Review
TA118; Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer was added to the static list in January 2010.
Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.
Recommendation 1.2 for cetuximab has since been updated and replaced by TA242, which was published in January 2012. This Static List Review deals with recommendation 1.1 from TA118.
No substantial new evidence has been identified that would lead to a change in the existing recommendations.
As a result, we have contacted stakeholders who were involved in the last review proposal for this appraisal to inform them that we have decided that recommendation 1.1 from TA118 should remain on the static list and no further action is required at this time.
However, if NICE is notified of a significant change to the evidence base at any stage in the future, this could trigger a formal review proposal.
November 2015
This page was last updated: